Author: gammy

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

TOKYO, Mar 27, 2026 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced

More

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

TOKYO and NEW YORK, NY., Mar 27, 2026 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation

More

NEC Orchestrating Future Fund Invests in U.S.-based AGI7, Provider of “Alpha Vision” Platform for Autonomous Operations of AI Agents in Physical Spaces

TOKYO, Mar 25, 2026 – (JCN Newswire via SeaPRwire.com) – NEC Corporation’s (NEC; TSE: 6701) ecosystem-based corporate venture capital (CVC) fund, NEC Orchestrating Future Fund (NOFF), has invested in AGI7, Inc. (AGI7), provider of the Physical AI platform “Alpha Vision.” This platform enables AI

More